When RIPK3 kinase activity is intact and MLKL is available, the proteasome inhibitors MG132 and Bortezomib can trigger RIPK3-dependent necroptosis in Jurkat T-cell leukemia cell lines without inhibiting caspase 8. This evidence concerns the gene RIPK3 and T-cell leukemia.